Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study
Background. S-1 plus cisplatin has been established to be standard first-line chemotherapy for advanced gastric cancer in Japan. The optimal second-line treatment refractory to S-1 plus cisplatin remains unclear. Methods. We retrospectively studied the efficacy, toxicity, and survival of irinotecan...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2012/640401 |
id |
doaj-c02738dc579840bd90d7da48ffee4617 |
---|---|
record_format |
Article |
spelling |
doaj-c02738dc579840bd90d7da48ffee46172020-11-24T23:48:48ZengHindawi LimitedGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/640401640401Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective StudyKohei Ogawa0Ayumu Hosokawa1Akira Ueda2Seiko Saito3Hiroshi Mihara4Takayuki Ando5Shinya Kajiura6Mitsuhiro Terada7Yuji Tsukioka8Naoki Horikawa9Takashi Kobayashi10Masayuki Note11Kunihiro Sawasaki12Junya Fukuoka13Toshiro Sugiyama14Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanDepartment of Gastroenterology, Kouseiren Takaoka Hospital, 5-10 Eiraku-cho, Takaoka, Toyama 933-8555, JapanDepartment of Surgery, Takaoka City Hospital, 4-1 Takaramachi, Takaoka, Toyama 933-8550, JapanDepartment of Surgery, Takaoka City Hospital, 4-1 Takaramachi, Takaoka, Toyama 933-8550, JapanDepartment of Surgery, Takaoka City Hospital, 4-1 Takaramachi, Takaoka, Toyama 933-8550, JapanDepartment of Surgery, Takaoka City Hospital, 4-1 Takaramachi, Takaoka, Toyama 933-8550, JapanDepartment of Surgery, Takaoka City Hospital, 4-1 Takaramachi, Takaoka, Toyama 933-8550, JapanDepartment of Surgical Pathology, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanBackground. S-1 plus cisplatin has been established to be standard first-line chemotherapy for advanced gastric cancer in Japan. The optimal second-line treatment refractory to S-1 plus cisplatin remains unclear. Methods. We retrospectively studied the efficacy, toxicity, and survival of irinotecan plus mitomycin C in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin. Results. Twenty-four patients were studied. Prior chemotherapy was S-1 plus cisplatin in 15 patients, S-1 plus cisplatin and docetaxel in 8, and 5-fluorouracil plus cisplatin with radiotherapy in 1. The overall response rate was 17.4%. The median overall survival was 8.6 months, and the median progression-free survival was 3.6 months. Grade 3 or 4 toxicities included leukopenia (33%), neutropenia (50%), anemia (33%), thrombocytopenia (4%), anorexia (13%), diarrhea (4%), and febrile neutropenia (13%). Conclusion. A combination of irinotecan and mitomycin C is potentially effective in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin.http://dx.doi.org/10.1155/2012/640401 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kohei Ogawa Ayumu Hosokawa Akira Ueda Seiko Saito Hiroshi Mihara Takayuki Ando Shinya Kajiura Mitsuhiro Terada Yuji Tsukioka Naoki Horikawa Takashi Kobayashi Masayuki Note Kunihiro Sawasaki Junya Fukuoka Toshiro Sugiyama |
spellingShingle |
Kohei Ogawa Ayumu Hosokawa Akira Ueda Seiko Saito Hiroshi Mihara Takayuki Ando Shinya Kajiura Mitsuhiro Terada Yuji Tsukioka Naoki Horikawa Takashi Kobayashi Masayuki Note Kunihiro Sawasaki Junya Fukuoka Toshiro Sugiyama Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study Gastroenterology Research and Practice |
author_facet |
Kohei Ogawa Ayumu Hosokawa Akira Ueda Seiko Saito Hiroshi Mihara Takayuki Ando Shinya Kajiura Mitsuhiro Terada Yuji Tsukioka Naoki Horikawa Takashi Kobayashi Masayuki Note Kunihiro Sawasaki Junya Fukuoka Toshiro Sugiyama |
author_sort |
Kohei Ogawa |
title |
Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study |
title_short |
Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study |
title_full |
Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study |
title_fullStr |
Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study |
title_full_unstemmed |
Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study |
title_sort |
irinotecan plus mitomycin c as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and cisplatin: a retrospective study |
publisher |
Hindawi Limited |
series |
Gastroenterology Research and Practice |
issn |
1687-6121 1687-630X |
publishDate |
2012-01-01 |
description |
Background. S-1 plus cisplatin has been established to be standard first-line chemotherapy for advanced gastric cancer in Japan. The optimal second-line treatment refractory to S-1 plus cisplatin remains unclear. Methods. We retrospectively studied the efficacy, toxicity, and survival of irinotecan plus mitomycin C in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin. Results. Twenty-four patients were studied. Prior chemotherapy was S-1 plus cisplatin in 15 patients, S-1 plus cisplatin and docetaxel in 8, and 5-fluorouracil plus cisplatin with radiotherapy in 1. The overall response rate was 17.4%. The median overall survival was 8.6 months, and the median progression-free survival was 3.6 months. Grade 3 or 4 toxicities included leukopenia (33%), neutropenia (50%), anemia (33%), thrombocytopenia (4%), anorexia (13%), diarrhea (4%), and febrile neutropenia (13%). Conclusion. A combination of irinotecan and mitomycin C is potentially effective in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin. |
url |
http://dx.doi.org/10.1155/2012/640401 |
work_keys_str_mv |
AT koheiogawa irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT ayumuhosokawa irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT akiraueda irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT seikosaito irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT hiroshimihara irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT takayukiando irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT shinyakajiura irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT mitsuhiroterada irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT yujitsukioka irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT naokihorikawa irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT takashikobayashi irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT masayukinote irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT kunihirosawasaki irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT junyafukuoka irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy AT toshirosugiyama irinotecanplusmitomycincassecondlinechemotherapyforadvancedgastriccancerresistanttofluoropyrimidineandcisplatinaretrospectivestudy |
_version_ |
1725484462446215168 |